• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Evolus Inc (NQ: EOLS )

16.32 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus Inc

< Previous 1 2 3 4 5 6 7 Next >
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
From Evolus
Via Business Wire
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024
From Evolus
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
March 21, 2024
Via Benzinga
Recap: Evolus Q4 Earnings
March 07, 2024
Via Benzinga
Earnings Outlook For Evolus
March 06, 2024
Via Benzinga
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
February 14, 2024
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. 
Via Investor's Business Daily
Evolus Inc. (NASDAQ: EOLS) Leading the Way in Wednesday Trading Based on Percentage Gain
January 17, 2024
Via Investor Brand Network
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
March 11, 2024
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From Evolus
Via Business Wire
EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023
March 07, 2024
EOLS stock results show that Evolus missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
March 07, 2024
From Evolus
Via Business Wire
Earnings Scheduled For March 7, 2024
March 07, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
Evolus Announces Results from European Head-to-Head Filler Trial
March 01, 2024
From Evolus
Via Business Wire
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
February 27, 2024
From Evolus
Via Business Wire
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
February 22, 2024
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2024
From Evolus
Via Business Wire
Novo Nordisk Stock Just Earned A 92 RS Rating; Gapped Up On Earnings
February 01, 2024
Novo Nordisk ADR sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 29, 2024
Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped... 
Via Benzinga
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
January 29, 2024
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported... 
Via Benzinga
Topics Stocks
Exposures US Equities
Evolus Set For Promising 2024: Analysts Maintain Positive Outlook On Botox Alternative Maker
January 17, 2024
Evolus beats Q4 revenue expectations, up 40% YoY at $61M. Full-year 2023 hits $202M, exceeding guidance. Analysts bullish on Evolus. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 17, 2024
Via Benzinga
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
January 16, 2024
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2024
From Evolus
Via Business Wire
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
January 11, 2024
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing... 
Via Benzinga
Exposures Product Safety
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
January 04, 2024
From Evolus
Via Business Wire
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
December 20, 2023
From Evolus
Via Business Wire
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
December 12, 2023
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to... 
Via Benzinga
Exposures Product Safety
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From Evolus
Via Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From Evolus
Via Business Wire
Why Toast Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 08, 2023
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares climbed 96% to $0.2921 after falling over 7% on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap